Piperazine, 2-hydroxy-1,2,3-propanetricarboxylate (3:2), hydrate.
Piperazine citrate (3:2) hydrate [41372-10-5].
Anhydrous 642.66 [144-29-6].
» Piperazine Citrate contains not less than 98.0 percent and not more than 100.5 percent of (C4H10N2)3· 2C6H8O7, calculated on the anhydrous basis.
Packaging and storage Preserve in well-closed containers.
Add the following:USP Reference standards 11
USP Piperazine Citrate RS.USP32
Change to read:Identification
B: In the test for Chromatographic purity, the principal spot in the chromatogram of Test solution 2, observed after spraying with the ninhydrin solutions, corresponds in RF value, color, and size to that in the chromatogram of Standard solution 1.
C:USP32 It responds to the tests for Citrate 191.
Water, Method I 921: not more than 12.0%.
Delete the following:Primary amines and ammonia Dissolve 500 mg in 10 mL of water. Add 1 mL of 2.5 N sodium hydroxide, 1 mL of acetone, and 1 mL of sodium nitroferricyanide TS. Mix, and allow to stand for 10 minutes, accurately timed. Determine the absorbance of this solution at 520 nm and at 600 nm, using a blank consisting of the same quantities of the same reagents, but substituting water for the sodium hydroxide solution. The ratio A600/A520 is not more than 0.50 (equivalent to about 0.7% of primary amines and ammonia).USP32
Add the following:Chromatographic purity
Solvent Prepare a mixture of 13.5 N ammonium hydroxide and dehydrated alcohol (3:2).
Standard solution 1 Prepare a solution of USP Piperazine Citrate RS in Solvent containing 10 mg per mL.
Standard solution 2 Prepare a solution of ethylenediamine in Solvent containing 0.25 mg per mL.
Standard solution 3 Prepare a solution of triethylenediamine in Solvent containing 0.25 mg per mL.
Test solution 1 Prepare a solution of Piperazine Citrate in Solvent containing 100 mg per mL.
Test solution 2 Mix 1 mL of Test solution 1 and 9 mL of Solvent.
Resolution solution Prepare a solution in Solvent containing 0.25 mg of triethylamine and 10 mg of Piperazine Citrate per mL.
Procedure Apply separate 5-µL portions of Standard solution 1, Standard solution 2, Standard solution 3, Resolution solution, Test solution 1, and Test solution 2 to a suitable thin-layer chromatographic plate (see Chromatography 621), coated with a 0.25-mm layer of chromatographic silica gel. Allow the spots to dry, and develop the chromatograms in a solvent system consisting of a freshly prepared mixture of acetone and 13.5 N ammonium hydroxide (80:20) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and dry the plate at 105. Spray the plate with a 0.3% (w/v) solution of ninhydrin in a mixture of butyl alcohol and glacial acetic acid (100:3). Spray the plate again with a 0.15% (w/v) solution of ninhydrin in dehydrated alcohol, dry the plate at 105 for 10 minutes, and examine the plate: any secondary spot in the chromatogram obtained from Test solution 1 is not more intense than the principal spot in the chromatogram obtained from Standard solution 2 (0.25%). Spray the plate with 0.1 N iodine TS, allow to stand for 10 minutes, and examine the plate: any spot corresponding to triethylenediamine in the chromatogram obtained from Test solution 1 is not more intense than the principal spot in the chromatogram obtained from Standard solution 3 (0.25%). In a valid test, the chromatogram obtained from the Resolution solution shows a spot due to triethylenediamine clearly separated from the principal spot. Disregard any spot at the origin of any chromatogram.USP32
Change to read:Assay Dissolve about 200 mg of Piperazine Citrate, accurately weighed, in 100 mL of glacial acetic acid, USP32 warming slightly if necessary to effect solution. Add crystal violet TS, and titrate with 0.1 N perchloric acid VS. Perform a blank determination, and make any necessary correction. Each mL of 0.1 N perchloric acid is equivalent to 10.71 mg of (C4H10N2)3·2C6H8O7.
Auxiliary Information Please check for your question in the FAQs before contacting USP.
USP32NF27 Page 3314Pharmacopeial Forum: Volume No. 34(1) Page 106